EBS Share Price

Open 27.50 Change Price %
High 27.81 1 Day 0.27 0.98
Low 26.63 1 Week 1.01 3.77
Close 27.77 1 Month 1.41 5.35
Volume 550120 1 Year -9.28 -25.05
52 Week High 44.38
52 Week Low 24.47
EBS Important Levels
Resistance 2 28.86
Resistance 1 28.41
Pivot 27.40
Support 1 27.13
Support 2 26.68
NYSE USA Most Active Stocks
BAC 22.16 1.47%
BAC 22.16 1.47%
BAC 22.16 1.47%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
AMD 9.45 8.87%
AMD 9.45 8.87%
AMD 9.45 8.87%
PCS 11.84 -0.92%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
IPI 1.82 22.15%
IPI 1.82 22.15%
IPI 1.82 22.15%
IL 13.12 16.42%
SAB 7.20 12.50%
SAB 7.20 12.50%
SAB 7.20 12.50%
SAB 7.20 12.50%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Emergent Biosolutions, Inc. (NYSE: EBS)

EBS Technical Analysis 4
As on 6th Dec 2016 EBS Share Price closed @ 27.77 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 33.34 & Sell for SHORT-TERM with Stoploss of 28.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
EBS Target for December
1st Target up-side 30.85
2nd Target up-side 33.72
3rd Target up-side 36.59
1st Target down-side 22.67
2nd Target down-side 19.8
3rd Target down-side 16.93
EBS Other Details
Segment EQ
Market Capital 529524064.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.emergentbiosolutions.com
EBS Address
EBS
2273 Research Boulevard
Suite 400
Rockville, MD 20850
United States
Phone: 301-795-1800
Fax: 301-795-1899
Interactive Technical Analysis Chart Emergent Biosolutions, Inc. ( EBS NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Emergent Biosolutions, Inc.
EBS Business Profile
Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; and PreviThrax, a recombinant protective antigen anthrax vaccine product candidate. The Biosciences segment markets WinRho SDF, to treat immune thrombocytopenic purpura, an autoimmune platelet disorder; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; VARIZIG for post-exposure prophylaxis of chickenpox; and Episil to treat pain associated with oral mucositis. It is also developing Otlertuzumab, a mono-specific protein therapeutic in Phase II clinical trials for the treatment of chronic lymphocytic leukemia; and IXINITY, a therapeutic to prevent bleeding episodes in people with hemophilia B. In addition, this segment provides contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is based in Rockville, Maryland.